Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-59,330
Closed -$950K 980
2024
Q1
$950K Hold
59,330
﹤0.01% 672
2023
Q4
$1.62M Buy
59,330
+2,560
+5% +$67.6K 0.01% 620
2023
Q3
$1.38M Buy
56,770
+1,400
+3% +$37.3K 0.01% 661
2023
Q2
$1.54M Buy
55,370
+1,800
+3% +$58.9K 0.01% 693
2023
Q1
$1.78M Buy
53,570
+1,500
+3% +$57.6K 0.01% 678
2022
Q4
$1.6M Buy
52,070
+4,800
+10% +$151K 0.01% 734
2022
Q3
$1.62M Buy
47,270
+2,500
+6% +$107K 0.01% 744
2022
Q2
$1.55M Buy
44,770
+8,900
+25% +$314K 0.01% 913
2022
Q1
$1.58M Buy
35,870
+400
+1% +$19.3K 0.01% 892
2021
Q4
$2.23M Buy
35,470
+8,200
+30% +$695K 0.01% 853
2021
Q3
$2.87M Buy
27,270
+4,900
+22% +$703K 0.01% 697
2021
Q2
$3.96M Buy
22,370
+600
+3% +$96.5K 0.02% 649
2021
Q1
$2.9M Sell
21,770
-500
-2% -$77.4K 0.01% 651
2020
Q4
$3.01M Buy
22,270
+4,600
+26% +$468K 0.02% 596
2020
Q3
$1.47M Hold
17,670
0.01% 825
2020
Q2
$1.45M Buy
17,670
+4,700
+36% +$318K 0.01% 830
2020
Q1
$668K Buy
+12,970
New +$676K ﹤0.01% 872

Other funds holding ZLAB

Aviva's ZLAB Position: Q2 2024 in Review

Aviva sold out of Zai Lab (ZLAB) in Q2 2024, closing a stake of 59,330 shares — an estimated $950K sold.

Aviva first reported a position in ZLAB in Q1 2020 and held it in 17 quarters. The position peaked at $3.96M in Q2 2021. 105 funds tracked by Wall St. Rank hold ZLAB as of Q2 2024.

  • Aviva reported no remaining Zai Lab position as of Q2 2024 after selling out during the quarter.
  • Aviva sold 59,330 Zai Lab shares in Q2 2024, an estimated $950K.
  • Aviva first reported a position in Zai Lab in Q1 2020 and held it in 17 quarters.
  • Aviva's Zai Lab position peaked at $3.96M in Q2 2021.
  • 105 funds tracked by Wall St. Rank held Zai Lab as of Q2 2024.

Based on Aviva's 13F filing for Q2 2024, filed 2 Aug 2024.